MR
Merck & Co
MRK·NYSERahway NJFounded 189169,000 employees
Large CappharmaPublicOncologyInfectious DiseaseCardiology
Platform: Keytruda & ADCs
Market Cap
$290B
All Drugs
14
Clinical Trials
25
Failed / Terminated
6
FDA Approved
1
Stock Price & Catalysts (MRK)
Loading MRK stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| MRK-7739 | MRK-7739 | Preclinical | 2 | IL-23 | Crohn'sNMOSD | ||
| MRK-1380 | MRK-1380 | Preclinical | 2 | SHP2 | Prostate Ca | ||
| Voxarasimod | MRK-9258 | Phase 1/2 | 2 | CD19 | NB | ||
| Gozelemzoparlimab | MRK-2195 | Phase 2 | 1 | FXIa | Heart FailureSCLC | ||
| Doxarasimod | MRK-3789 | NDA/BLA | 1 | FGFR | BCCSCLC | ||
| MRK-3732 | MRK-3732 | Phase 1 | 2 | TYK2 | Ewing Sarcoma | ||
| MRK-8368 | MRK-8368 | Phase 3 | 3 | ALK | CLLSCLC | ||
| MRK-853 | MRK-853 | Phase 1 | 2 | PRMT5 | Endometrial CaRSV | ||
| MRK-6781 | MRK-6781 | Approved | 2 | TIGIT | PsA | ||
| Rimamavacamten | MRK-8748 | Phase 1 | 1 | PI3Kα | Ewing Sarcoma | ||
| MRK-3745 | MRK-3745 | Phase 2 | 2 | WRN | CKDPSP | ||
| MRK-2473 | MRK-2473 | Phase 1/2 | 1 | Nectin-4 | AMLNB | ||
| Ribotuximab | MRK-1295 | Phase 2 | 2 | GPRC5D | CMLRB | ||
| MRK-5413 | MRK-5413 | Phase 1 | 2 | GLP-1R | NASHWM |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (24)